DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
<p><strong>Objective:</strong> The main purpose of this study is to evaluate the potential clinical impact of pharmacogenetic testing on the reduction of the toxicity in patients treated with fluoropyrimidines. This will be achieved by comparing the frequency of adverse events and...
Saved in:
Main Authors: | Ana Hernández-Guío (Author), M.ª Ángeles Bernabéu-Martínez (Author), Andrés Corno-Caparrós (Author), M.ª Teresa Aznar-Saliente (Author), Manuel Bonete-Sánchez (Author), Miguel Ángel Calleja-Hernández (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Challenges in DPYD Test Implementation in Patients Treated with Fluoropyrimidines are DPYD Genotype Arriving on Time? [Letter]
by: López López-Cepero M, et al.
Published: (2023) -
Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
by: Anthi Maslarinou, et al.
Published: (2023) -
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
by: Angela Wu, et al.
Published: (2023) -
Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
by: Georgia Ragia, et al.
Published: (2023) -
Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
by: Ursina B. M. Begré, et al.
Published: (2022)